Cost-effectiveness of the addition of CDK4/6 inhibitors to standard endocrine therapy in first-line treatment of women with advanced HR+/HER2− breast cancer in Mexico

被引:0
作者
Mariana Molina-Jaimes
Antonio Galindo-González
Haydeé Cristina Verduzco-Aguirre
Sergio Bautista-Arredondo
Gustavo Reyes-Terán
Enrique Soto-Perez-de-Celis
机构
[1] Instituto Nacional de Salud Pública,Department of Hemato
[2] Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán,Oncology
[3] Secretaría de Salud,Department of Geriatrics
[4] Comisión Coordinadora de los Institutos Nacionales de Salud y Hospitales de Alta Especialidad,undefined
[5] Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán,undefined
来源
Clinical and Translational Oncology | 2024年 / 26卷
关键词
Breast cancer; Cost-effectiveness analysis; Palbociclib; Ribociclib; Abemaciclib;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:239 / 244
页数:5
相关论文
共 62 条
[41]  
Awada A(undefined)undefined undefined undefined undefined-undefined
[42]  
Forrester T(undefined)undefined undefined undefined undefined-undefined
[43]  
Tripathy D(undefined)undefined undefined undefined undefined-undefined
[44]  
Im SA(undefined)undefined undefined undefined undefined-undefined
[45]  
Colleoni M(undefined)undefined undefined undefined undefined-undefined
[46]  
Franke F(undefined)undefined undefined undefined undefined-undefined
[47]  
Bardia A(undefined)undefined undefined undefined undefined-undefined
[48]  
Harbeck N(undefined)undefined undefined undefined undefined-undefined
[49]  
Buehler AM(undefined)undefined undefined undefined undefined-undefined
[50]  
Castilho G(undefined)undefined undefined undefined undefined-undefined